Innate Pharma (NASDAQ:IPHA) Shares Down 1% - Here's What Happened

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Get Free Report) shares traded down 1% during mid-day trading on Wednesday . The stock traded as low as $1.83 and last traded at $1.90. 4,654 shares traded hands during trading, a decline of 98% from the average session volume of 186,471 shares. The stock had previously closed at $1.92.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and set a $11.00 price objective (down previously from $11.50) on shares of Innate Pharma in a research note on Thursday, April 24th.

Innate Pharma Trading Down 5.3%

The company has a debt-to-equity ratio of 2.52, a quick ratio of 2.60 and a current ratio of 2.60. The stock's 50 day simple moving average is $2.09 and its two-hundred day simple moving average is $1.99.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.